Evidence map›Paper›PMID 31152044›Full record

ArticleBMJ open2019

Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study.

Temmy Sunyoto, Julien Potet, Margriet den Boer, Koert Ritmeijer, Jose A R Postigo, Raffaella Ravinetto, Fabiana Alves, Albert Picado, Marleen Boelaert

Abstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Market Formation in a Global Health Transition.Environmental innovation and societal transitions · 2021
    Article
  7. Review
  8. The global procurement landscape of leishmaniasis medicines.PLoS neglected tropical diseases · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Temmy SunyotoPublic Health Department, Institute of Tropical Medicine, Antwerpen, Belgium.ORCID 0000-0003-0369-8830
Julien PotetMedical Department, Médecins Sans Frontières Access Campaign, Paris, France.
Margriet den BoerMedical Department, Artsen zonder Grenzen, Amsterdam, The Netherlands.
Koert RitmeijerMedical Department, Artsen zonder Grenzen, Amsterdam, The Netherlands.
Jose A R PostigoNeglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland.
Raffaella RavinettoPublic Health Department, Institute of Tropical Medicine, Antwerpen, Belgium.
Fabiana AlvesVL Clinical Program, Drugs for Neglected Disease Initiative, Geneva, Switzerland.
Albert PicadoInstituto de Salud Global Barcelona, Barcelona, Spain.
Marleen BoelaertPublic Health Department, Institute of Tropical Medicine, Antwerpen, Belgium.

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectivesTo understand stakeholders' perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa, and to identify key bottlenecks to improve the supply of commodities for neglected tropical diseases.

designDesk reviews and qualitative in-depth interview study with purposive sampling.

methodsA landscape analysis through literature and desk review was performed. Next, 29 representatives from international organisations, non-governmental agencies, national control programmes from six countries (Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda) and manufacturers were interviewed between May and July 2018. Participants were selected purposively and expanded through a snowballing technique.Data analysis was aided by NVivo, applying the framework method as a part of the thematic content analysis approach.

resultsThe barriers along the visceral leishmaniasis (VL) supply chain were identified as emerging themes, grouped across supply chain activities and health systems component(s). Stakeholders expressed the perception of progress, but bottlenecks persist. VL medicines, in general, lack multisource production capacity and with small market volume, expansion of suppliers is difficult. Procurement is plagued by forecasting difficulties, complex regulatory policies and procedures, and distribution challenges. Weak communication and coordination across different levels resulted in shortages and loss of trust among different actors. Cross-cutting issues spanned from limited political and resource commitment due to low awareness and limited in-country capacity. However, study respondents were optimistic to pursue several remedies, most importantly to build bridges between supply and demand sides through continued dialogue and collaborations. Diagnostics supply has mostly been overlooked; thus, improved investment in this area is needed.

conclusionsAddressing supply barriers in eastern Africa requires consistent, specific efforts at the global and national levels, progressing from current partnerships and agreements. Priority actions include pooled procurement, improved forecast, and increased commitment and resources. Sustainability remains an elusive goal, yet to be integrated into discussions moving forward.

Indexed as

Agglutination TestsAntiprotozoal AgentsDrug IndustryDrug UtilizationGovernment RegulationHumansLeishmaniasis, VisceralPoint-of-Care SystemsQualitative ResearchStakeholder ParticipationAntiprotozoal Agentshealth policyleishmaniasispublic healthqualitative researchsupply chaintropical medicine

Identifiers

PMID31152044
PMCPMC6549606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.